Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.

Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.